Research in Respiratory

Presentations supported by Boehringer Ingelheim

American Thoracic Society Meeting 2020

NOTICE: This website is intended for healthcare professionals only. The posters accessed through this page may discuss and/or present information on investigational uses of nintedanib for which effectiveness and safety have not been established. Nintedanib is indicated for (i) treatment for idiopathic pulmonary fibrosis; (ii) treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype; and (iii) slowing the rate of decline of pulmonary function in patients with systemic sclerosis-associated interstitial lung disease.

Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

Effect of nintedanib in patients with limited and extensive systemic sclerosis-associated interstitial lung disease (SSc-ILD): data from the SENSCIS trial

^{Goh N, Denton CP, Lynch DA, Maher TM, Smith V, Prasse A, Cottin V, Spiera R, Stock C, Gahlemann M, Alves M, Wells AU, on behalf of the SENSCIS trial investigators}

Lung function decline in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by time since first non-Raynaud symptom: subgroup analysis of the SENSCIS trial

^{Distler O, Khanna D, Allanore Y, Hoffmann-Vold AM, Sfikakis P, Valentini G, Maher TM, Aringer M, Meng L, Alves M, Gahlemann M, Quaresma M, Kuwana M, on behalf of the SENSCIS trial investigators}

Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) by body mass index (BMI) at baseline: subgroup analysis of the SENSCIS trial

^{Jouneau S, Lescoat A, Crestani B, Riemekasten G, Kondoh Y, Smith V, Patel NM, Huggins JT, Stock C, Gahlemann M, Alves M, Denton CP, on behalf of the SENSCIS trial investigators}

Effect of nintedanib on progression of systemic sclerosis-associated interstitial lung disease (SSc-ILD) beyond 52 weeks: data from the SENSCIS trial

^{Maher TM, Distler O, Allanore Y, Ogura T, Varga J, Vettori S, Crestani B, von Wangenheim U, Quaresma M, Alves M, Stowasser S, Assassi S, on behalf of the SENSCIS trial investigators}

Chronic Fibrosing Interstitial Lung Diseases (ILDs) with Progressive Phenotype

Effect of nintedanib on FVC decline in patients with progressive fibrosing ILDs: data from the INBUILD trial

^{Cottin V, Inoue Y, Kolb M, Rosas I, Tomassetti S, Quaresma M, Goeldner R, Schlenker-Herceg R, Brown KK, on behalf of the INBUILD trial investigators}

Effects of nintedanib on dyspnea, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial

^{Swigris JJ, Richeldi L, Wijsenbeek M, Kreuter M, Nunes H, Suda T, James A, Rohr KB, Quaresma M, Flaherty KR, on behalf of the INBUILD trial investigators}

Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?

^{Brown KK, Walsh SLF, Devaraj A, Song JW, Wuyts WA, Valenzuela C, Goeldner R, Stowasser S, Schlenker-Herceg R, Wells AU, on behalf of the INBUILD trial investigators}

Effect of nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses from the INBUILD trial

^{Kolb M, Flaherty KR, Silva RS, Prasse A, Patel NM, Vancheri C, Quaresma M, Goeldner R, Stowasser S, Schlenker-Herceg R, Wells AU, on behalf of the INBUILD trial investigators}

Safety and tolerability of nintedanib in patients with fibrosing ILDs: a comparison of the INBUILD and INPULSIS trials

^{Martinez FJ, Costabel U, Jenkins RG, Belperio JA, Kitamura H, Molina Molina M, Tschoepe I, Coeck C, Haeufel T, Quaresma M, Cottin V, on behalf of the INBUILD trial investigators}

Improving our understanding of progressive fibrosing interstitial lung diseases (ILDs): design of the ILD-PRO Registry

^{Palmer SM, Neely ML, Belperio JA, Bender S, Culver DA, de Andrade J, O'Brien EC, Roman J, Snyder LD, Todd JL, Whelan TPM, Leonard TB, Conoscenti CS, on behalf of the ILD-PRO Registry investigators}

Study design of a Phase III, randomized, placebo-controlled trial of nintedanib in children and adolescents with clinically significant fibrosing interstitial lung disease (ILD)

^{Young L, Brown K, Griese M, Deutsch G, Warburton D, DeBoer E, Cunningham S, Clement A, Schwerk N, Flaherty K, Voss F, Schmid U, Schlenker-Herceg R, Verri D, Stowasser S, Clerisme-Beaty E, Dumistracel M, Schiwek M, Tetzlaff K, Deterding R}

Identifying key considerations for early identification of interstitial lung disease: a Delphi consensus study

^{Hunninghake M, Goldin J, Lazarus H, Kropski J, Pipavath S, Rosas I, Yadav R, Wells A, on behalf of the ILA Delphi survey group}

Idiopathic Pulmonary Fibrosis (IPF)

Disease progression events in trials of nintedanib in patients with idiopathic pulmonary fibrosis

^{Nathan SD, Costabel U, Lancaster LH, Corte TJ, Nunes H, Schinzel B, Quaresma M, Wells AU}

Effect of nintedanib in subgroups based on combined pulmonary fibrosis and emphysema (CPFE) index at baseline

^{Cottin V, Ryerson CJ, Flaherty KR, Lee JS, Corte TJ, Schinzel B, Orsatti L, Quaresma M, Wells AU}

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and multiple comorbidities

^{Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E}

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis: subgroup analyses by TORVAN stage

^{Torrisi SE, Wijsenbeek M, Orsatti L, Quaresma M, Schinzel B, Kreuter M, Vancheri C}

Gene expression profiling in patients with idiopathic pulmonary fibrosis (IPF) in the INMARK trial

^{Selman M, Jenkins RG, White ES, Cottin V, Nishioka Y, Noth I, Prasse A, Song JW, Strobel B, Leparc G, Ittrich C, Diefenbach C, Rohr KB, Stowasser S, Maher TM}

Gene expression profiling in patients with idiopathic pulmonary fibrosis (IPF) treated with nintedanib and sildenafil: data from the INSTAGE trial

^{Bonella F, Kolb M, White ES, Cottin V, de Andrade J, Glaspole I, Strobel B, Roy J, Ittrich C, Diefenbach C, Rohr KB, Quaresma M, Martinez FJ}

Association of circulating proteins with death or lung transplant in the IPF-PRO Registry cohort

^{Todd JL, Neely ML, Overton R, Mulder H, Roman J, Lasky JA, de Andrade J, Gulati M, Huang H, Leonard TB, Hesslinger C, Noth I, Belperio JA, Flaherty KR, Palmer SM, on behalf of the IPF-PRO Registry investigators}

Relationship between mRNA-microRNA interactions and forced vital capacity in patients with idiopathic pulmonary fibrosis

^{Noth I, Roy J, Schmid R, Vinisko R, Strobel B, Neely ML, Hesslinger C, Belperio JA, Flaherty KR, Salisbury ML, Oldham J, Palmer SM, Todd JL, Leonard TB, on behalf of the IPF-PRO Registry investigators}

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry

^{Snyder LD, Mosher C, Holtze CH, Lancaster LH, Flaherty KR, Noth I, Neely ML, Hellkamp AS, Bender S, Conoscenti CS, de Andrade JA, Whelan TPM, on behalf of the IPF-PRO Registry investigators}

In-hospital mortality in patients with idiopathic pulmonary fibrosis

^{Judy J, Durheim MT, Bender S, Neely ML, Baumer D, Robinson SB, Conoscenti CS, Leonard TB, Lazarus HM, Palmer SM}

Impact of pre-transplant anti-fibrotic therapy for IPF upon lung transplant outcomes

^{Astor T, Goldberg H, Snyder LD, Courtwright A, Hachem R, Pena T, Zaffiri L, Criner GJ, Budev M, Thaniyavarn T, Lazarus HM, Bender S, Barakat A, Breeze J, LaCamera P}

Chronic Obstructive Pulmonary Disease (COPD)

COPD maintenance therapy with tiotropium/olodaterol versus LABA/ICS: an assessment of the risk of treatment escalation and adverse outcomes in over 40,000 patients

^{Quint JK, Montonen J, Esposito D, He X, Koerner L, Wallace L, de la Hoz A, Miravitlles M}

Benefits of tiotropium/olodaterol over tiotropium alone in delaying clinically significant deterioration in patients with COPD

^{Rabe KF, Chalmers J, Miravitlles M, Kocks J, Tsiligianni I, de la Hoz A, Xue W, Wedzicha J, Singh D, Ferguson GT}

Evaluation of real-world health care resource utilization (HCRU) among patients with COPD initiating combination tiotropium/olodaterol versus triple therapy

^{Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J}

Evaluation of clinical outcomes within baseline exacerbation subgroups among patients with COPD initiating combination tiotropium/olodaterol versus triple therapy

^{Palli SR, Anderson AJ, Le L, Frazer M, DuCharme M, Buikema AR, Franchino-Elder J}

FOOTPRINTS^® study methodology and baseline characteristics: a 3-year longitudinal study to phenotype patients with COPD

^{Crapo JD, Gupta A, Lynch DA, Vogel-Claussen J, Watz H, Turner AM, Mroz R, Janssens W, Ludwig-Sengpiel A, Beck M, Koegler H, Langellier B, Eleftheraki A, Risse F, Diefenbach C}

Blood eosinophil levels in Chinese patients with chronic obstructive pulmonary disease: pooled analysis of 7 Phase III/IV randomized controlled trials

^{Zheng J, Jian W, Su L, Xue W}